PSI ToxSIG Webinar: Beyond the looking glass - Interpreting animal welfare & behaviour by monitoring & assessing mice activity data
Analysing continuously collected locomotive activity data to interpret mice welfare and behaviour.
For our joint event with the DIA, Paul Gallo presented his work on the consistency of treatment effects in multiregional trials, and James Hung presented on some of the considerations needed in the design and analysis of multi-regional trials.
Joint PSI Pharmaceutical Statistics & DIA Statistics Community
DIA Chair: Susan Duke, GSK
Speaker: Paul Gallo, Novartis:
DIA (industry perspective): Assessment of Consistency of Treatment Effects in Multiregional Clinical Trials
Hui Quan, Mingyu Li, Joshua Chen, Paul Gallo, et al
Drug Information Journal, Vol. 44, pp. 617-632, 2010
Abstract | Paper+ | Slides
PSI Chair: Stephen Pyke, Pfizer
Speaker: James Hung, FDA
PSI (FDA perspective): Consideration of regional differences in design and analysis of multi-regional trials
James Hung, Sue-Jane Wang, Robert O’Neill
Pharmaceutical Statistics, Vol. 9, Issue 3, pp. 173-178, 2010
Abstract | Paper+ | Slides
+ Papers available to view from 29th March 2011 to 26th April 2011.
For a flier advertising the event, please click here.
Analysing continuously collected locomotive activity data to interpret mice welfare and behaviour.
Our next journal club features two papers on the topic of Survival Analysis. For each of these published papers there will be a 20 minute presentation by author followed by a 10 minute discussion.
The field of data visualization is the intersection of data journalism, statistics, graphic design, computer science, neuroscience, and cognitive psychology. We will focus on the latter two fields of data visualization as it relates to data visualization: neuroscience and cognitive psychology.
Hear about potential strategies to handle non-proportional hazards and delayed treatment effects from experts in the field.
As a statistician in the Biostatistics and Programming Department, you will be responsible for the methodological and statistical aspects of projects in early clinical development in order to optimize the early development plan and ensure its coherence.
By joining our company, in this role you will apply your skills and experience in support of developing scientifically based arguments aiming to provide fair accessibility to our company’s drugs and vaccines making a real difference in patient’s lives.
As a Director of Statistics, you will be accountable for guiding statisticians in their work, performing senior review of documentation and output deliveries, providing oversight and advising on best practices approach to statistics for clinical trials.